

PRESS RELEASE

Lunatus and AFYX Therapeutics A/S Announce Distribution and Sales Collaboration

Hørsholm, Denmark – April 23rd., 2025

Lunatus and AFYX Therapeutics A/S are pleased to announce a new distribution and sales collaboration for AFYX's induction of labor product, Gefena (Misoprostol 25µg tablet). Under this agreement, Lunatus will distribute, commercialize and supply Gefena in the following countries: United Arab Emirates, Qatar, Kuwait, Oman, Kingdom of Saudi Arabia, Bahrain, Iraq, and Jordan. Gefena is expected to receive EU regulatory approval in Q4 2025. Gefena is designed to induce labor in pregnant women who have surpassed their scheduled delivery date.

About Lunatus and AFYX Therapeutics A/S

Lunatus is dedicated to partnering with leading biopharmaceutical companies, broadening and accelerating global patient access to innovative treatments utilizing its unique core competencies and know-how to effectively introduce cutting edge therapies and pharmaceuticals.
www.lunatus.com.

At AFYX, "Reversed Innovation" is our core value.

As a leader in the biopharmaceutical industry, we focus on repurposing existing products or technologies to address new or previously overlooked medical conditions.

Visit www.afyxtx.com.

For more information please contact:

Lunatus:

Mina Ashraf

Mina.ashraf@lunatus.com

Maricel Magtibay

Maricel@lunatus.com

+971 4 399 4755

+971 4 208 9333

AFYX Therapeutics A/S

Pia Laursen

pcl@afyxtx.com

+45 2320 1914

CLAUS MØLLER-SAN PEDRO

CEO & Founder



info@afyxtx.com



Slotsmarken 11, 1.tv, 2970 Hørsholm,

WE FIND NEW

INDICATIONS FOR EXISTING TECHNOLOGIES